About 20% of lupus patients have disease onset during childhood, and pediatric lupus patients are more at risk for severe disease and worse long-term outcomes, according to a Seattle Children’s news release. The most common form of lupus for children, systemic lupus erythematosus, is the target for the CAR T-cell drug candidate.
“Despite recent advances in lupus management, many patients have lupus that is resistant to current treatment regimens,” the release said. “Even among treatment-responsive subjects, available medications need to be taken chronically with little expectation of durable remission off therapy.”
The FDA authorized Seattle Children’s to launch the clinical trial, which is named Reversing Autoimmunity through Cell Therapy and is scheduled to start this summer.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
